Teva Pharmaceutical Industries Limited Sponsored ADR Aktie News

When examined over long stretches, stocks stand atop the pedestal in terms of annualized return, relative to all other asset classes. But this doesn't mean the Dow Jones Industrial Average (^DJI -1.33%), S&P 500 (^GSPC 0.13%), and Nasdaq Composite (^IXIC -0.13%) move from Point A to B in a straight line.

TEVA has 121% upside from its share price today. Retiring early is possible, and may be easier than you think.

For more than a century, the stock market has been the premier wealth creator for investors. But this doesn't mean stocks move higher in a straight line.

The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading...

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take direct aim at drug imports. The post Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports appeared first on Investor's Business Daily.

PARSIPPANY, N.J. and TEL AVIV, April 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for AJOVY® (fremanezumab-vfrm) to expand the indication to include the prevention of episodic migr...

PARSIPPANY, N.J. and TEL AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS...

It's hard to believe, but the first quarter of 2025 is rapidly coming to a close. After doing a quick portfolio checkup, I found that I have stocks that have gained as much as 40% already this year, but I also have a few that are down nearly 30%.